Novartis Pharma (encorafenib (LGX818))

Business Data, Corporate Office and Headquarter Address

About

Novartis Pharma (encorafenib (LGX818)) is Buildings and Property in United States that focus on a key protein business. They cover business area such as a key protein, pathway, several key cellular activity, proliferation, differentiation, migration, survival, angiogenesis.

Business Type

Buildings and Property

Country

United States

Founded

-

Company Focus

A Key Protein

Website

-

Corporate Office and Headquarter Office address:

Boulder, CO
United States

Phone number:

Private

Office Opening Hours*:

Monday 9.30 - 17.00
Tuesday 9.30 - 17.00
Wednesday 9.30 - 17.00
Thursday 9.30 - 17.00
Friday 9.30 - 17.00
Saturday Closed
Sunday Closed

Business Coverage

a key proteinpathwayseveral key cellular activityproliferationdifferentiationmigrationsurvivalangiogenesis

* We use standard office opening hours in near Novartis Pharma (encorafenib (LGX818))'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.

Novartis Pharma (encorafenib (LGX818)) Frequently Asked Questions

What or who is Novartis Pharma (encorafenib (LGX818))?

Novartis Pharma (encorafenib (LGX818)) is Buildings and Property business from United States that founded in - ( years old in ), Novartis Pharma (encorafenib (LGX818)) business is focusing on A Key Protein.

Where is Novartis Pharma (encorafenib (LGX818)) headquarter and corporate office address?

Novartis Pharma (encorafenib (LGX818)) headquarter office and corporate office address is located in Boulder, CO United States.

Where is Novartis Pharma (encorafenib (LGX818)) country origins?

Novartis Pharma (encorafenib (LGX818)) was founded in United States.

What is A Key Protein business focus on?

In , Novartis Pharma (encorafenib (LGX818)) is currently focus on a key protein sector.

Disclaimer: This website is not affiliated with Novartis Pharma (encorafenib (LGX818)), any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.